According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
Separately, HC Wainwright set a $18.00 price target on Sutro Biopharma and gave the stock a “buy” rating in a research report on Friday, May 17th.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.06). As a group, analysts forecast that Trillium Therapeutics will post -1.69 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in TRIL. Geode Capital Management LLC increased its position in Trillium Therapeutics by 164.0% during the fourth quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after buying an additional 16,541 shares during the last quarter. Two Sigma Investments LP acquired a new position in Trillium Therapeutics during the fourth quarter worth approximately $35,000. Jane Street Group LLC acquired a new position in shares of Trillium Therapeutics in the fourth quarter valued at approximately $43,000. NEA Management Company LLC grew its position in shares of Trillium Therapeutics by 68.0% in the first quarter. NEA Management Company LLC now owns 2,100,000 shares of the biotechnology company’s stock valued at $1,386,000 after purchasing an additional 850,000 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Trillium Therapeutics in the first quarter valued at approximately $73,000. 24.99% of the stock is currently owned by hedge funds and other institutional investors.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.